SYRA · Syra Health Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.27M | - | $2.25M | $1.97M | $1.86M | - | $2.25M | $979.2K | $1.75M | - |
| Cost of Revenue | $1.30M | - | $1.13M | $1.19M | $1.27M | - | $1.59M | $851.1K | $1.57M | - |
| Gross Profit | $971.3K | - | $554.5K | $752.9K | $589.2K | - | $668.3K | $350.0K | $179.3K | - |
| R&D | $6.9K | - | $816 | $29.7K | $37.2K | - | $34.8K | $277.9K | $277.5K | - |
| SG&A | $213.0K | - | $252.4K | $289.1K | $287.3K | - | $288.3K | $208.4K | $402.3K | - |
| Total Operating Expenses | $780.3K | - | $786.7K | $816.1K | $1.06M | - | $1.10M | $1.74M | $1.62M | - |
| D&A | $1.1K | - | $5.4K | $6.0K | $6.8K | - | $25.5K | $12.3K | $12.5K | - |
| Operating Income | $191.0K | - | ($232.2K) | ($63.2K) | ($473.3K) | - | ($428.9K) | ($784.0K) | ($1.44M) | - |
| Interest Expense | $2.5K | - | $1.9K | $3.9K | $3.2K | - | $14.2K | $3.7K | $4.1K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | $241.0K | - | ($225.9K) | ($63.6K) | ($472.3K) | - | ($417.5K) | ($802.8K) | ($1.45M) | - |
| EPS - Basic | $0.02 | - | ($0.02) | ($0.01) | ($0.04) | - | ($0.06) | ($0.18) | ($0.22) | - |
| EPS - Diluted | $0.02 | - | ($0.02) | ($0.01) | ($0.04) | - | ($0.06) | ($0.21) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.92M | $1.61M | $1.98M | $2.31M | $2.49M | $2.40M | $2.70M | $36.4K | $3.24M | $3.28M |
| Accounts Receivable | $869.1K | $918.4K | $926.3K | $680.8K | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | $557.1K | $325.0K | $101.7K | $212.9K | $500.1K | $645.6K | - |
| Current Assets | $3.93M | $2.74M | $3.21M | $3.43M | $3.65M | $3.35M | $4.06M | $2.83M | $4.45M | $4.78M |
| Total Assets | $3.94M | $2.77M | $3.26M | $3.47M | $3.72M | $3.68M | $4.43M | $3.24M | $4.55M | $4.92M |
| Current Liabilities | $1.58M | $674.7K | $1.05M | $1.06M | $1.27M | $613.5K | $877.8K | $901.2K | $1.10M | $910.1K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.58M | $674.7K | $1.05M | $1.06M | $1.27M | $800.8K | $1.09M | $1.15M | $1.10M | $910.1K |
| Stockholders' Equity | $2.36M | $2.10M | $2.21M | $2.41M | $2.46M | $2.88M | $3.33M | $2.09M | $3.45M | $4.01M |
| Retained Earnings | ($9.48M) | ($9.72M) | ($9.59M) | ($9.36M) | ($9.30M) | ($8.82M) | ($8.32M) | ($7.90M) | ($6.51M) | ($5.06M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.36M | - | - | - | $158.2K | - | - | - | ($800.7K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($5.6K) | - |
| Financing Cash Flow | ($54.4K) | - | - | - | ($63.1K) | - | - | - | $764.2K | - |
| CapEx | - | - | - | - | - | - | - | - | $5.6K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($806.4K) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 42.7% | - | 24.6% | 38.2% | 31.7% | - | 29.7% | 35.7% | 10.2% | - |
| Operating margin | 8.4% | - | -10.3% | -3.2% | -25.5% | - | -19.0% | -80.1% | -82.4% | - |
| EBITDA margin | 8.4% | - | -10.1% | -2.9% | -25.1% | - | -17.9% | -78.8% | -81.7% | - |
| Net margin | 10.6% | - | -10.0% | -3.2% | -25.4% | - | -18.5% | -82.0% | -82.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -46.0% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.56 | - |
| R&D / Revenue | 0.3% | - | 0.0% | 1.5% | 2.0% | - | 1.5% | 28.4% | 15.8% | - |
| SG&A / Revenue | 9.4% | - | 11.2% | 14.7% | 15.5% | - | 12.8% | 21.3% | 23.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 6.1% | - | -6.9% | -1.8% | -12.7% | - | -9.4% | -24.8% | -31.8% | - |
| Return on equity | 10.2% | - | -10.2% | -2.6% | -19.2% | - | -12.5% | -38.4% | -42.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.48 | 4.06 | 3.05 | 3.25 | 2.88 | 5.46 | 4.63 | 3.14 | 4.04 | 5.25 |
| Quick ratio | 2.48 | 4.06 | 3.05 | 3.25 | 2.88 | 5.46 | 4.63 | 3.14 | 4.04 | 5.25 |
| Cash ratio | 1.85 | 2.39 | 1.88 | 2.18 | 1.97 | 3.90 | 3.07 | 0.04 | 2.94 | 3.60 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 77.6x | - | -121.9x | -16.4x | -146.6x | - | -30.2x | -210.2x | -354.2x | - |
| Equity multiplier | 1.67 | 1.32 | 1.48 | 1.44 | 1.52 | 1.28 | 1.33 | 1.55 | 1.32 | 1.23 |
| Liabilities / Assets | 0.40 | 0.24 | 0.32 | 0.30 | 0.34 | 0.22 | 0.25 | 0.35 | 0.24 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | 0.58 | - | 0.69 | 0.57 | 0.50 | - | 0.51 | 0.30 | 0.39 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 140d | - | 150d | 126d | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | 170d | 94d | - | 49d | 214d | 150d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 10.8x | - | - | - | - | - | - | - | - | - |
| P / B | 1.2x | - | 0.5x | 0.5x | 1.2x | - | 0.9x | 2.9x | 2.6x | - |
| P / S | 1.2x | - | 0.5x | 0.7x | 1.6x | - | 1.4x | 6.1x | 5.1x | - |
| EV / EBITDA | -0.9x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 22.4% | - | 0.0% | 101.1% | 6.0% | - | 48.8% | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 64.9% | - | -17.0% | 115.1% | 228.6% | - | 20.5% | - | - | - |
| Operating income growth (YoY) | - | - | 45.9% | 91.9% | 67.2% | - | -23.7% | - | - | - |
| Net income growth (YoY) | - | - | 45.9% | 92.1% | 67.4% | - | -17.8% | - | - | - |
| EPS growth (YoY) | - | - | 66.7% | 95.2% | 81.8% | - | 25.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -3.8% | -27.1% | -33.7% | 15.4% | -28.8% | -28.3% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$7.23M totalPopulation Health$5.32M · 73.7%
Healthcare Workforce$1.90M · 26.3%
Peer comparison
Same SIC group: Services-Employment Agencies
Comparing Syra Health Corp against the 4 most active filers in the same SIC group.